A new weight loss biotech launched with $410 million and three assets from China. Roche's Chugai penned a deal to develop ...
Our fair value estimate for WuXi is HKD 24.60 per share. WuXi has been growing at a CAGR of 53.3% for the past eight years. Although its USD 20.5 billion total backlog revenue supports our growth ...
WuXi Biologics employees have once again exemplified their deep-rooted commitment to the local community, delivering ...
WuXi upgraded its WuXiBody platform in bispecific antibody discovery to address the growing global demand for these complex ...
JPMorgan upgraded Wuxi Biologics (WXXWY) to Overweight from Neutral with a price target of HK$20, up from HK$13, citing expected order growth ...
WuXi AppTec, the Shanghai-based biotech giant, has sold its South Philly-based WuXi Advanced Therapies contract manufacturing ...
MSD acquires WuXi Vaccines' Dundalk facility with a €500 million investment, creating 1,000 new jobs across Ireland and ...
Wuxi Biologics (WXXWY) plans to sell its Irish vaccine facility to Merck (MRK) for around $500M ahead of potential U.S. legislation that would ...
Candid Therapeutics is continuing its mission to flesh out a pipeline of T-cell engagers in record time, signing a ...
GlobalData on MSN3d
Candid Therapeutics signs $925m T cell engager deal with WuXi BiologicsUS-based Candid Therapeutics has signed another T-cell engager (TCE) partnership, this time with Chinese biotech WuXi ...
The transaction is expected to close in the first half of 2025, subject to the satisfaction of customary closing conditions.
DPA International on MSN3d
Merck to buy WuXi Biologics' Irish vaccine facility for $500 millionWuXi Biologics, a Chinese biopharmaceuticals company, announced on Monday the sale of its WuXi Vaccines facility in Ireland ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback